Randomized controlled trials in health technology assessment: overkill or overdue?
about
The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial LesionsFound in translation: Integrating laboratory and clinical oncology researchFactors affecting the implementation of complex and evolving technologies: multiple case study of intensity-modulated radiation therapy (IMRT) in Ontario, Canada.Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.Investment in radiotherapy infrastructure positively affected the economic status of an oncology hospital.Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review.The potential of helical tomotherapy in the treatment of head and neck cancer.What is the impact of innovation on output in healthcare with a special focus on treatment innovations in radiotherapy? A literature review.Charged-particle therapy in cancer: clinical uses and future perspectives.Proton therapy in paediatric oncology: an Irish perspective.The European Union's Ambient and Assisted Living Joint Programme: An evaluation of its impact on population health and well-being.Point/Counterpoint. Within the next 10-15 years protons will likely replace photons as the most common type of radiation for curative radiotherapy.RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison.New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy.The role of medical physicists in clinical trials: More than quality assurance.Locating and targeting moving tumors with radiation beams.Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
P2860
Q26770254-1B7846F1-3038-4A20-8716-96CCBF3B38F2Q28744471-907A3D03-89CB-4FB1-922C-B59A8218889AQ33975698-C23963A0-2297-4B84-8738-F0765D502EABQ34696349-91F7E25C-5D5C-4C47-A497-013D22EB79E0Q37392426-09AB99B7-5761-40C5-9702-2676CF07E3C9Q37672787-98E786F9-0D29-4880-9F0C-073694F04476Q38426070-0288226D-61FB-4C6D-B3D7-EE52600D9127Q38637605-DB9252C2-6F44-42CD-8A9C-E75FACD96A39Q38746213-A34EF2EA-8BA9-488A-BCC2-F6C0C1D8A831Q38981759-5397195B-70A6-4F43-8D00-47EBFC9AC408Q39050175-BB7DB76C-6AA0-4F45-B40F-C85C0133FD66Q40031228-A14A5A30-C016-43D9-B916-59B05CCFBB33Q41033896-88ADC4CF-6C01-4717-A97E-DEE0456AA0EEQ41561562-B700C216-1C0E-4569-A6EA-9A76D2665749Q42625823-99686BBF-0CF1-4944-97BA-FA6B7F287621Q46804908-79CC6FF6-8693-412B-8530-37691756D119Q47887111-EBF98E6F-C4A9-41DD-8923-590F9B9D033A
P2860
Randomized controlled trials in health technology assessment: overkill or overdue?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Randomized controlled trials in health technology assessment: overkill or overdue?
@ast
Randomized controlled trials in health technology assessment: overkill or overdue?
@en
type
label
Randomized controlled trials in health technology assessment: overkill or overdue?
@ast
Randomized controlled trials in health technology assessment: overkill or overdue?
@en
prefLabel
Randomized controlled trials in health technology assessment: overkill or overdue?
@ast
Randomized controlled trials in health technology assessment: overkill or overdue?
@en
P2860
P1476
Randomized controlled trials in health technology assessment: overkill or overdue?
@en
P2093
Søren M Bentzen
P2860
P304
P356
10.1016/J.RADONC.2008.01.012
P577
2008-01-30T00:00:00Z